Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting
April 18 2023 - 3:01PM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose
mission is to develop medicines that meaningfully improve and
extend the lives of patients facing deadly diseases, today
announced a summary of presentations at the American Association
for Cancer Research (AACR) Annual Meeting, taking place April
14-19, 2023 in Orlando, FL.
“We are delighted to share multiple datasets related to our
imipridone platform’s potential at this year’s AACR annual meeting
among leading cancer researchers,” said Mike Sherman, Chief
Executive Officer of Chimerix. “Data presented by Chimerix and
our collaborators included preclinical data that further support
ONC201’s mechanism of action as an anti-cancer agent with the
ability to cross the blood-brain barrier; human clinical data that
demonstrate its clinical efficacy; and a trial design to
demonstrate clinical benefit in this very vulnerable patient
population.”
“These data provide additional evidence for the potential
benefit of ONC201 in patients with the H3 K27M mutation,” said Carl
Koschmann, MD, Associate Assistant Professor of Pediatrics at the
University of Michigan. “This is the first report of any therapy
reversing the direct consequence of the oncogenic H3 K27M mutation
in tumor tissue from glioma patients and we are excited to further
understand these findings and association with activity of
ONC201.”
Results presented by Dr. Koschmann demonstrated that H3
K27M-mutant glioma patients treated with ONC201 experienced a
statistically significant reversal of the H3 K27 trimethyl-loss (H3
K27me3-loss) epigenetic signature throughout their tumor compared
to patients who did not receive ONC201. Gliomas with the H3
K27M-mutation undergo H3 K27me3-loss, which is a negative
prognostic variable among gliomas and thought to be a central
pathogenic hallmark of the disease.1 Concordant findings were also
reported in preclinical models that were mechanistically linked to
specific metabolic changes induced in tumors by ONC201.
Other presentations at the conference highlighted preclinical
oncology studies related to the imipridone platform performed by
Chimerix and collaborators at the Brown University Cancer Center.
The ongoing ACTION trial, a global Phase 3 clinical trial of ONC201
in newly diagnosed H3 K27M-mutant diffuse glioma, was also
highlighted. Further information regarding the data presented at
AACR can be found on the Publications page of the Chimerix
corporate website.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to
develop medicines that meaningfully improve and extend the lives of
patients facing deadly diseases. The Company’s most advanced
clinical-stage development program, ONC201, is in development for
H3 K27M-mutant glioma.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that are subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. Forward-looking statements
include those relating to, among other things, the potential
mechanism of action of ONC201 and its activity as an anti-cancer
agent. Among the factors and risks that could cause actual results
to differ materially from those indicated in the forward-looking
statements are risks related to the timing and completion of the
Phase 3 ACTION study of ONC201, and additional risks set forth in
the Company's filings with the Securities and Exchange
Commission. These forward-looking statements represent the
Company's judgment as of the date of this release. The Company
disclaims, however, any intent or obligation to update these
forward-looking statements.
CONTACTS: Michelle
LaSpaluto919 972-7115ir@chimerix.comWill O’ConnorStern Investor
Relations212-362-1200will@sternir.com
- World Health Organization 2021 Classification of Central
Nervous System
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024